Location · New Haven, CT
Clinical trials in New Haven, CT
189 recruiting studies have a site in New Haven, and 88 of them accept healthy volunteers.
189 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb
- Location
- New Haven, CT + 39 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Incyte Corporation
- Location
- New Haven, CT + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Vega Therapeutics, Inc
- Location
- New Haven, CT + 13 other US sites
- Eligibility basics
- Ages 12–75
- Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Inari Medical
- Location
- New Haven, CT + 32 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Mannkind Corporation
- Location
- New Haven, CT + 9 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- New Haven, CT + 39 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery
Intuitive Surgical
- Location
- New Haven, CT + 5 other US sites
- Eligibility basics
- Ages 16–75
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- New Haven, CT + 39 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
Insulet Corporation
- Location
- New Haven, CT + 10 other US sites
- Eligibility basics
- Ages 14–75
- Recruiting
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
W.L.Gore & Associates
- Location
- New Haven, CT + 30 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- New Haven, CT + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
- Location
- New Haven, CT + 10 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
ViiV Healthcare
- Location
- New Haven, CT + 32 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Priovant Therapeutics, Inc.
- Location
- New Haven, CT + 44 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
Medtronic Cardiovascular
- Location
- New Haven, CT + 27 other US sites
- Eligibility basics
- Ages 20+
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- New Haven, CT + 112 other US sites
- Eligibility basics
- Ages 45+
- Recruiting
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
Medtronic - MITG
- Location
- New Haven, CT + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney…
Alexion Pharmaceuticals, Inc.
- Location
- New Haven, CT + 28 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Monument Therapeutics Limited
- Location
- New Haven, CT + 14 other US sites
- Eligibility basics
- Ages 17–30
- RecruitingPhase 3
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Rapamycin Holdings Inc.
- Location
- New Haven, CT + 17 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
argenx
- Location
- New Haven, CT + 16 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Zucara Therapeutics Inc.
- Location
- New Haven, CT + 36 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
SELUTION4BTK Trial
M.A. Med Alliance S.A.
- Location
- New Haven, CT + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Calcilytix Therapeutics, Inc., a BridgeBio company
- Location
- New Haven, CT + 3 other US sites
- Eligibility basics
- Ages 0 mo–17